Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroœsophageal junction

By J. Macdonald, S. Smalley, J. Benedetti, S.A Hundhal, N. C. Estes, G.N Stemmermannn, D. Haller, J. Ajani, L. Gunderson, J. Jessup and 1 more. 2002

1,373 citations recorded by the source corpus.

Subfields: Biotechnology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1fae5abcf2530d88917b7f3b70a32ab0c88ed2c6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Japanese Gastric Cancer Association

Citations in the corpus

• Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. (2010, methodology): “A solution is to include all categories more advanced than cT1 as previously reported by the MAGIC(6) and other trials.(21,22) This approach is pragmatic because the discrimination of early gastric cancer seems to be more reliable than the discrimination within the categories cT2 or cT3 by endoscopi”
• Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma (2004, background): “A recent trial comparing gastrectomy with or without chemoradiation demonstrated a significant survival advantage for adjuvant therapy.(8) Because adjuvant therapy focuses on specific areas of potential recurrence (locoregional, peritoneal, or distant/systemic), understanding and predicting the patt”
• Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. (2008, background): “shown benefit in selected individual trials in patients with gastric and gastroesophageal junction cancers.(1,2)”
• Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. (2012, methodology): “This study’s primary analysis in 2001 demonstrated significant improvement in RFS and OS with adjuvant radiochemotherapy.(24) This update, with more than 10 years of follow-up, confirms the benefits of radiochemotherapy and explores associations of this type of therapy in selected subsets of patient”
• Gastric cancer treatment: recent progress and future perspectives (2023, background): “Adjuvant chemoradiotherapy (CRT) was once adopted in North America, according to the results of the phase III INT0116 trial [30].”
• Gastric cancer: epidemiology, prevention, classification, and treatment (2018, background): “The median recurrence-free survival time has been 30 months in the chemo-radiotherapy group and 19 months in the surgery alone group.(95) Although adjuvant radiotherapy and chemotherapy is recommended in the United States, in the European countries, the treatment has been limited to cases with subop”
• Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. (2011, result): “This reduction in the risk of mortality is comparable with that obtained with combined regimens for adjuvant chemotherapy intheMedicalResearchCouncilAdjuvantGastricInfusionalChemotherapy (MAGIC) trial(14) and the Intergroup 0116 (INT-0116) trial.(15) Whether the results of this study can be extrapol”
• Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. (2004, background): “erative chemoradiotherapy, which has recently been suggested as the standard of care treatment in the United States after a curative resection of gastric adenocarcinoma.(34) Because only 10% of these patients had the advised D2 lymph node dissection and 54% of the patients in that trial had a D0 lym”
• Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, methodology): “The North American Intergroup-0116 trial demonstrated that adjuvant therapy with 5-FU/leucovorin (Q28) plus conventionally fractionated RT (45 Gy in 25 fractions) resulted in improved OS years compared with surgery alone, (50% 3-year survival for patients treated with CRT versus 41% for those treate”
• Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. (2008, result): “ence with upper abdominal radiation therapy reporting a 35% risk of major or minor deviation from protocolprescribed radiation therapy, most of which required correction prior to the start of radiation therapy due to the risk of toxic effects on critical organs or failure to treat the appropriate ta”